Welcome to our dedicated page for SELLAS Life Sciences Group SEC filings (Ticker: SLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SELLAS Life Sciences Group, Inc. filings document a Nasdaq-listed clinical biopharmaceutical company developing cancer therapeutics, including GPS and SLS009 programs in acute myeloid leukemia. Form 8-K reports cover operating results, financial condition, corporate updates, clinical program disclosures, and material agreements.
The filing record also includes capital-structure disclosures for common stock and warrants, warrant inducement agreements and exercise proceeds, share-count updates, and facility-related agreements. Proxy materials document annual meeting proposals, stockholder voting procedures, and governance matters.
SELLAS Life Sciences Group, Inc. reported an equity award to a senior executive. SVP and Chief Development Officer Dragan Cicic received an award of 300,000 restricted stock units on January 7, 2026. These RSUs are scheduled to vest 25% on December 1, 2026, and 25% on each December 1 thereafter until fully vested, as long as he remains in service with the company on each vesting date. Following this grant, Cicic is shown as beneficially owning 557,805 shares of common stock, held directly. The transaction was reported at a price of $0.00 per share, reflecting the nature of the RSU award rather than a market purchase.
SELLAS Life Sciences Group, Inc. reported that its CFO, John Thomas Burns, received an award of 300,000 restricted stock units of common stock on January 7, 2026. The Form 4 shows this as an acquisition at a price of $0.00 per share, reflecting an equity compensation grant rather than an open‑market purchase.
The RSUs are scheduled to vest over four years: 25% on December 1, 2026 and 25% on each December 1 thereafter, as long as he remains in service with the company through each vesting date. After this grant, Burns is reported to beneficially own 554,327 shares of common stock, held directly.
SELLAS Life Sciences Group director Katherine Bach Kalin reported receiving 50,000 shares of common stock as a stock-based award. The Form 4 shows the transaction occurred on January 7, 2026 and was coded as an acquisition at a price of $0.00 per share, reflecting a grant rather than an open-market purchase.
According to the disclosure, the grant represents 50,000 restricted stock units that will vest in full on December 1, 2026, provided she continues to serve on the company’s board of directors through that date. After this award, she beneficially owns 154,400 shares of SELLAS common stock, held directly.
SELLAS Life Sciences Group, Inc. director Jane Wasman reported receiving an award of 50,000 restricted stock units of common stock on January 7, 2026. The filing states that these RSUs will vest in full on December 1, 2026, provided she continues to serve on the company’s Board of Directors through that date. The award was reported at a price of $0.00 per share, reflecting a grant of equity compensation rather than a market purchase. Following this grant, she beneficially owns 92,900 shares of SELLAS common stock in direct ownership.
SELLAS Life Sciences Group, Inc. reported that it estimates unaudited cash and cash equivalents of $71.8 million as of December 31, 2025. This figure is preliminary and may change once year-end financial closing procedures and management reviews are completed. After December 31, 2025, the company received approximately $26.5 million in proceeds from the exercise of common stock warrants, adding further liquidity. As of January 7, 2026, SELLAS had 170,282,026 shares of common stock outstanding.
SELLAS Life Sciences Group, Inc. reported an insider ownership change by its Chief Financial Officer, John Thomas Burns. On 12/03/2025, the company withheld 58,592 shares of common stock at $1.5 per share to cover the CFO’s tax withholding obligations related to vesting Restricted Stock Units. This reduced his holdings but did not involve an open-market sale. Following the transaction, Burns beneficially owns 254,327 shares of SELLAS common stock directly.
SELLAS Life Sciences Group, Inc. director reports open-market stock purchase. Director Katherine Bach Kalin bought 63,400 shares of SELLAS common stock on 11/19/2025 in an open-market transaction coded as a purchase. The filing shows a weighted average purchase price of $1.59 per share, with individual trades executed between $1.555 and $1.625 per share. Following this transaction, she beneficially owns 104,400 shares of SELLAS common stock in direct ownership.
SELLAS Life Sciences Group, Inc. furnished an 8-K announcing it issued a press release with financial results for the quarter ended September 30, 2025 and a corporate update. The press release is attached as Exhibit 99.1, dated November 12, 2025. The company states the information in Item 2.02 and Exhibit 99.1 is furnished and shall not be deemed filed under the Exchange Act or incorporated by reference into other SEC filings.
SELLAS Life Sciences Group (SLS) reported Q3 2025 results. The company posted a net loss of $6.8 million (basic and diluted $0.06 per share) as operating expenses eased slightly to $7.1 million, with research and development at $4.2 million and general and administrative at $2.9 million. For the nine months, net loss was $19.2 million and operating cash use was $23.5 million.
Cash and cash equivalents were $44.3 million as of September 30, 2025. Subsequent financing included an October 2025 warrant inducement for net proceeds of about $29.1 million, which, together with quarter-end cash, is expected to fund current planned operations for at least the next twelve months. Earlier in 2025, the company raised $23.1 million net via a registered direct offering and $22.0 million net via a September warrant inducement, with additional warrant exercises contributing $8.7 million.
Pipeline updates highlight the Phase 3 REGAL study for GPS continuing per independent monitoring recommendations toward a final analysis at 80 events, and SLS009 Phase 2a data meeting primary endpoints with FDA guidance to initiate a randomized first-line AML study. As of November 11, 2025, shares outstanding were 142,442,239.